SCHEMBL479724

SCHEMBL479724

CNC(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.67
HDAC8 Q9BY41 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
TSHR P16473 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
HPGD P15428 1/20 0.61
HTT P42858 1/20 0.61
TP53 P04637 1/20 0.60
PLK1 P53350 7/20 0.59
CA2 P00918 2/20 0.55
ALDH1A1 P00352 1/20 0.54
MMP13 P45452 1/20 0.53
SRD5A2 P31213 3/20 0.52
MRGPRX4 Q96LA9 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA3 P07451 1/20 0.50
TYR P14679 1/20 0.50
DRD1 P21728 1/20 0.50
CA4 P22748 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL250247 0.89 HDAC6 (0.80) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL5375128 0.88 HPGD (0.85) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
Terephthalic Acid SCHEMBL28353337 0.84 TSHR (0.75) TSHRSMN1; SMN2HPGDTP53CA2
SCHEMBL6100 0.82 HDAC8 (0.62) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL16198923 0.82 HDAC6 (0.70) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL14115137 0.82 HDAC6 (0.70) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL25489176 0.81 HDAC8 (0.61) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL8237229 0.81 HDAC8 (0.61) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
SCHEMBL10759601 0.81 HDAC8 (0.61) HDAC2HDAC8HDAC6TSHRSMN1; SMN2
Terephthalic Acid SCHEMBL1204011 0.81 TSHR (0.92) TSHRSMN1; SMN2TP53CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110088108-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-06-14 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-111108109-A Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors 利奥制药有限公司 2020-05-05 CN claimed
EP-3551634-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP claimed
CN-110099905-A SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-06 CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 CN claimed
WO-2018108231-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO claimed
US-5602277-A Substituted benzene derivatives useful as neuraminidase inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 1997-02-11 US claimed
WO-1996030329-A1 SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARMACEUTICALS, INCORPORATED (US) 1996-10-03 WO claimed
US-20260070878-A1 TNKS2 INHIBITORS UNIV CORNELL (US) 2026-03-12 US disclosed
EP-4676600-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF Deliver Therapeutics, Inc. (US) 2026-01-14 EP disclosed
CN-114206335-B KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2025-03-11 CN disclosed
EP-4446314-A2 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2024-10-16 EP disclosed
WO-2024186579-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF DELIVER THERAPEUTICS, INC. (US) 2024-09-12 WO disclosed
US-4128713-A 6,7-Didehydro-PGI1 compounds THE UPJOHN COMPANY (US) 1978-12-05 US disclosed
US-4126744-A PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS THE UPJOHN COMPANY (US) 1978-11-21 US disclosed
US-4112224-A PROSTAGLANDIN THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4109082-A PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS THE UPJOHN COMPANY (US) 1978-08-22 US disclosed
US-4100192-A Inter-phenylene-PG amides THE UPJOHN COMPANY (US) 1978-07-11 US disclosed
US-4097489-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070878-A1 TNKS2 INHIBITORS TNKS, TNKS2, TNK1 HDAC2 1240/4885HDAC8 491/4885HDAC6 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.